NasdaqGS:MNMDPharmaceuticals
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD)
Mind Medicine (MindMed) has rebranded as Definium Therapeutics and, as of January 13, 2026, now trades on Nasdaq under the ticker “DFTX,” highlighting its focus on next-generation treatments for psychiatric and neurological disorders.
The company’s emphasis on DT120, an orally disintegrating tablet in three Phase 3 studies for generalized anxiety disorder and major depressive disorder, marks a clear pivot toward late-stage psychiatry drug development.
With this rebrand and late-stage focus...